What cancer care can learn from the NFL

Cara Livernois | | Health Exec | Economics

Superbowl Sunday, basically a holiday in the U.S., could teach us more than how to tackle the quarterback. In an article by Forbes, Kathy Giusti and Richard G. Hamermesh, Founder of the Multiple Myeloma Research Foundation, and Senior Fellow at Harvard Business School, explain what precision medicine can learn from the NFL.

Integrating itself into many American families, the NFL is a major part of their lives. Every year the NFL showcases how rivals face each other and battle to the top, a quality the field of cancer care and research lack. Giusti and Hamermesh review how the NFL factors of joined sponsor activities, a culture of shared values and competition can make a big impact on cancer care.

Read the full story below: 

What Precision Medicine Can Learn from the NFL

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Related Content

Merck spends up to $2B to license new weight loss drug with potential heart benefits
Insulet wins $452M in lawsuit against rivals over medical device trade secrets
Medical device company cuts 70% of staff in push to meet Medtronic obligations
Cleerly’s momentum continues as AI specialists raise $106M
Operations manager, doctors charged in $70M imaging kickback scheme
Private-equity watchdog warns against nominating Marc Rowan as Treasury Secretary

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.